Mavenclad, a drug used in the treatment of relapsing remitting multiple sclerosis (RRMS), has been listed on the Pharmaceutical Benefits Scheme (PBS) as of January 1. Through the PBS, the government will subsidise almost the entire cost of the drug, saving Australians with RRMS up to $54,000 per year. The treatment has been shown to have a positive effect on relapse rates and rates of brain shrinkage.

*Photograph: Joel Carrett/AAP: Scott Morrison with his brother-in-law, Gary Warren, as he announces the listing of multiple sclerosis drug Mavenclad on the Pharmaceutical Benefits Scheme.